RxDoctor Payments Data

Giovanni Llibre, MD

Internal Medicine · Boone, NCNPI 1871550905

Payments from drug & device makers

$1,010in general payments, 2019–2025

Across 45 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$311
  • Viiv Healthcare Company$198
  • AbbVie$71
  • GSK$63
  • Dexcom, Inc.$60
  • Otsuka America Pharmaceutical, Inc.$40
  • plus $267 from 13 others

What the payments were for

  • Food & beverage$99799%
  • Entertainment$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,010 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$927
Medicare patients
43
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$40,797
JardianceEmpagliflozin26$17,302
EliquisApixaban17$16,243
FarxigaDapagliflozin Propanediol16$10,679
Tresiba Flextouch U-100Insulin Degludec13$8,155
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,741
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl38$7,128
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,335
Humalog Kwikpen U-100Insulin Lispro14$1,929
Celecoxib24$1,170
Albuterol Sulfate HfaAlbuterol Sulfate42$1,012
Pregabalin27$808
Gabapentin60$731
Rosuvastatin Calcium42$674
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$40,79736 claims
AstraZenecaFarxiga$18$10,67916 claims
GSKTrelegy Ellipta$63$7,74111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →